Clinical trial · Observational
Evaluating Obesity-Mediated Mechanisms of Pancreatic Carcinogenesis in Minority Populations
NCT05687188CI-TRIAL-00112618active not recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 26, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260926-000001
Summary
Brief summary (as posted)
This study will evaluate obesity-mediated mechanisms of pancreatic carcinogenesis in minority populations.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood Sample Collection | Other | — | UNRESOLVED |
| Data Collection | Other | — | UNRESOLVED |
| Medical Image Collection | Other | — | UNRESOLVED |
| Tissue Sample Collection | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Retrospective Cohort
- description
- Retrospective chart review and sample analysis of both pathologically confirmed Pancreatic Ductal Adenocarcinoma (PDAC) cases and non-Cancer control cases.
- label
- Prospective Cohort
- description
- Blood samples, tissue samples and data will be collected from all participants as applicable.
- interventionNames
- Other: Blood Sample Collection
- Other: Tissue Sample Collection
- Other: Data Collection
- Other: Medical Image Collection
Primary outcomes (3)
- measure
- Assess molecular and radiological landscape of traditional PDAC tumors in the context of Race/Ethnicity
- timeFrame
- at 36 months
- description
- Investigators will compare gene prevalence, type and expression of genetic mutations and radiomic features in African American participants vs Non-Hispanic White participants
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adults 18 years of age or older at time of signing informed consent * Patients who self-report as African American, Non-Hispanic White * Patients who present to the gastrointestinal (GI) clinic, surgery, or endoscopy at a participating Florida Pancreas Collaborative (FPC) site or the University of Mississippi Medical Center (UMMC) with a clinical suspicion or diagnosis of a pancreatic tumor. Exclusion Criteria: * Patient under 18 years of age * Has no suspicion or diagnosis of a pancreatic cancer or tumor * Self-reported race/ethnicity other than African American or Non-Hispanic White.
References
Publications (0)
Data not yet available
No reference posted for this study.